ArticleBMC biotechnology2020
A self-aggregating peptide: implications for the development of thermostable vaccine candidates.
Article in BMC biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Resolving the differential distribution of structural proteins in baculovirus using single-molecule localization microscopy.The Journal of general virology · 2024Article
- An ambient-temperature stable nanoparticle-based vaccine for nasal application that confers long-lasting immunogenicity to carried antigens.Frontiers in immunology · 2022Article
- Development of thermostable vaccine adjuvants.Expert review of vaccines · 2021Review
- Lyophilized yeast powder for adjuvant free thermostable vaccine delivery.Applied microbiology and biotechnology · 2021Article
- SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.Frontiers in immunology · 2021Review
- Self-Assembling Nanovaccine Enhances Protective Efficacy Against CSFV in Pigs.Frontiers in immunology · 2021Article
- Rationally Designed Protein Building Blocks for Programmable Hierarchical Architectures.Frontiers in chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of biomaterials has been expanded to improve the characteristics of vaccines. Recently we have identified that the peptide PH
resultsIn the present study we demonstrate the use of a system developed to generate nano and microparticles carrying as a fusion protein peptides or proteins of interest to be used as vaccines. These particles are purified easily by centrifugation. Immunization of animals with the particles in the absence of adjuvant result in a robust and long-lasting immune response. Proteins contained inside the particles are maintained for over 1 year at ambient temperature, preserving their immunological properties.
conclusionThe rapid and efficient production of the particles in addition to the robust immune response they generate position this system as an excellent method for the rapid response against emerging diseases. The thermostability conferred by the particle system facilitates the distribution of the vaccines in developing countries or areas with no electricity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.